HSP-CAR30

HSP-CAR30 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy specifically engineered to target the CD30 protein, which is highly expressed on the surface of tumor cells in classical Hodgkin lymphoma and other CD30-positive lymphomas. Developed by academic research institutions in Europe, including the Josep Carreras Leukaemia Research Institute and IR Sant Pau, this therapy incorporates advanced genetic engineering strategies to enhance both the persistence and functionality of therapeutic T cells. The manufacturing process includes ex vivo modulation with interleukins IL-7, IL-15, and IL-21 to promote a high proportion of less-differentiated memory stem-like (TSCM) and central memory (TCM) T cells—cell types associated with long-term immune surveillance. By targeting a stable epitope within the nonsoluble part of CD30, HSP-CAR30 reduces tumor escape mechanisms such as antigen shedding. Clinical trials have demonstrated high overall response rates (~100%) and durable complete remissions (~55–60%) in heavily pretreated patients with relapsed or refractory disease[3][6][7][9]. The therapy has shown manageable safety profiles without dose-limiting toxicities or neurotoxicity.

Other names

autologous anti-CD30 CAR T cells HSP-CAR30CART30 (academic memory-enriched)